1 day Ago By Defense World Staff
Analysts at StockNews.com started coverage on shares of Catalent ( NYSE:CTLT – Get Free Report ) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.
Several other research firms have also weighed in on CTLT. Barclays upped their price target on Catalent from $47.00 to $63.
00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th.
Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $58.
08. Read Our Latest Report on CTLT Catalent Trading Up 0.4 % Insider Buying and Selling In related news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th.
The shares were sold at an average price of $58.76, for a total value of $534,010.88.
Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.
88. Following the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96.
The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.
74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.
54. The disclosure for this sale can be found here . In the last three months, insiders sold 13,409 shares of company stock valued at $782,923.
Company insiders own 0.31% of the company’s stock. Hedge Funds Weigh In On Catalent Institutional investors and hedge funds have recently added to or reduced their stakes in the company.
Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the period.
Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent during the second quarter worth $42,000. Mather Group LLC.
bought a new stake in Catalent in the 1st quarter valued at $52,000. Longfellow Investment Management Co. LLC raised its stake in shares of Catalent by 45.
7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares in the last quarter.
Finally, GAMMA Investing LLC lifted its holdings in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period.
About Catalent ( Get Free Report ) Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Read More Five stocks we like better than Catalent How to Effectively Use the MarketBeat Ratings Screener Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What is Insider Trading? What You Can Learn from Insider Trading Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter ..
